Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad[I/PPT-E1A] before radical prostatectomy for localized prostate cancer
NL-OMON24928Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2013
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Open-label trial of Ad[I/PPT-E1A] in prostate cancer (PCa) and prostate adenocarcinoma (3 arms), sponsored by Erasmus MC. Primary endpoint: Dose-limiting toxicity. Started Oct 2013; status: active, not recruiting.
02
Drugs
Ad[I/PPT-E1A]
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on NL-OMON24928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24928.